Product
CF101
Aliases
IB-MECA
2 clinical trials
2 indications
Indication
PsoriasisIndication
Rheumatoid ArthritisClinical trial
A Phase 2, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of the Safety and Activity of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque PsoriasisStatus: Completed, Estimated PCD: 2009-09-01
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid ArthritisStatus: Completed, Estimated PCD: 2007-04-01